CERO THERAPEUTICS HOLDINGS, INC. Operating Lease, Right-of-Use Asset, Amortization Expense
CERO THERAPEUTICS HOLDINGS, INC. (CERO) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $434.63 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-14
- 2026-06-30: Operating Lease, Right-of-Use Asset, Amortization Expense 6 month $434.63K.
- 2025-06-30: Operating Lease, Right-of-Use Asset, Amortization Expense 6 month $391.42K.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month |
|---|---|
| 2026-06-30 | $434.63K 10-Q · filed 2026-08-14 |
| 2025-06-30 | $391.42K 10-Q · filed 2026-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |